Biotech SPAC Social Capital Suvretta Holdings I files for a $200 million IPO

Social Capital Suvretta Holdings I, a blank check company formed by Chamath Palihapitiya and Kishen Mehta targeting the biotech sector, filed on Wednesday with the SEC to raise up to $200 million.

The Henderson, NV-based company plans to raise $200 million by offering 20 million shares at $10. The company is not offering units with warrants attached. At the proposed deal size, Social Capital Suvretta Holdings I would command a market value of $256 million.

The company is led by CEO and Chairman Chamath Palihapitiya, the founder and Managing Partner of Social Capital, and President and Director Kishen Mehta, who currently serves as the Portfolio Manager for the Averill strategy at Suvretta. The pair is also behind three other SPACs that filed concurrently with Social Capital Suvretta Holdings I (DNAB, DNAC, and DNAD). Outside of this partnership, Palihapitiya is active in the SPAC space, leading several past blank check IPOs (SPCE, OPEN, CLOV, IPOD.U, SOFI, and IPOF.U).

The company plans to target the biotech sector, focusing on therapeutics, novel platforms, and other modalities to help manage and treat brain and nervous system disorders, including neurologic and psychiatric diseases and pain management.

Social Capital Suvretta Holdings I was founded in 2021 and plans to list on the Nasdaq under the symbol DNAA. Morgan Stanley is the sole bookrunner on the deal.